RT Journal Article
SR Electronic
T1 The iHealth-T2D study: Statistical analysis plan for a cluster randomised controlled trial with intensive family-based lifestyle modification programme to reduce type 2 diabetes risk amongst South Asians
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.12.20229849
DO 10.1101/2020.11.12.20229849
A1 Mirthe Muilwijk
A1 Marie Loh
A1 Sara Mahmood
A1 Saranya Palaniswamy
A1 Samreen Siddiqui
A1 Wnurinham Silva
A1 Gary S. Frost
A1 Heather M. Gage
A1 Marjo-Riitta Jarvelin
A1 Ravindra P. Rannan-Eliya
A1 Sajjad Ahmed
A1 Sujeet Jha
A1 Anuradhani Kasturiratne
A1 Prasad Katulanda
A1 Khadija I. Khawaja
A1 Jaspal S. Kooner
A1 Ananda R. Wickremasinghe
A1 Irene G.M. van Valkengoed
A1 John C. Chambers
YR 2020
UL http://medrxiv.org/content/early/2020/11/15/2020.11.12.20229849.abstract
AB Background South Asians are at high risk of type 2 diabetes (T2D). Lifestyle modification is effective at preventing T2D amongst South Asians, but the approaches to screening and intervention are limited by high-costs, poor scalability and thus low impact on T2D burden. An intensive family-based lifestyle modification programme for prevention of T2D was developed. The aim of the iHealth-T2D trial is to compare the effectiveness of this programme with usual care.Methods The iHealth-T2D trial is designed as a cluster randomised controlled trial (RCT) conducted at 120 locations across India, Pakistan, Sri Lanka and the UK. A total of 3,682 South Asian men and women with age between 40-70 years without T2D but at elevated risk for T2D [defined by central obesity (waist circumference ≥95cm in Sri Lanka, or ≥100cm in India, Pakistan and UK) and/or prediabetes (HbA1c ≥6.0%)] were included in the trial. Here we describe in detail the statistical analysis plan (SAP), which was finalised before outcomes were available to the investigators. The primary outcome will be evaluated after three years of follow-up after enrolment to the study, and is defined as T2D incidence in the intervention arm compared to usual care. Secondary outcomes are evaluated both after one and three years of follow-up and include biochemical measurements, anthropometric measurements, behavioural components and treatment compliance.Discussion The iHealth-T2D trial will provide evidence whether an intensive family-based lifestyle modification programme in South Asians who are at high risk for T2D is effective in the prevention of T2D. The data from the trial will be analysed according to this pre-specified SAP.Ethics and dissemination The trial was approved by the international review board of each participating study site. Study findings will be disseminated through peer-reviewed publications and in conference presentations.Trial registration EudraCT 2016-001350-18. Registered 14 April 2016 https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ihealth-t2d/; ClinicalTrials.gov NCT02949739. Registered 31 October 2016, https://clinicaltrials.gov/ct2/show/NCT02949739, First posted 31/10/2016.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTrial registration: EudraCT 2016-001350-18. Registered 14 April 2016 https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ihealth-t2d/ ; ClinicalTrials.gov NCT02949739. Registered 31 October 2016, https://clinicaltrials.gov/ct2/show/NCT02949739, First posted 31/10/2016.Funding StatementThe iHealth-T2D trial was funded by the European Commission (Grant award 643774, January 2015 to December 2019).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Institutional Review Board in each participating country and at each research location before the start of the study. Information sheets and consent forms were made available in the major South Asian languages. Multilingual translators were available as required. Each participant provided informed consent. People unwilling or unable to provide consent were excluded from the study. India Max Healthcare Institutional Ethic Committee (ref: CT/MSSH/SKT-2/ENDO/IEC/14-40, date 22/04/16) Indian Council for Medical Research (ICMR, ref: 55/7/Indo-Foreign-Diab/2014-NCD-II, date 08/02/2016) Pakistan Punjab Institute of Cardiology Ethical Committee (ref: rtpgme-research-047, date 09/04/16) Services Institute of Medical Sciences Institutional Review Board (ref: IRB/2016/222/SIMS, date 12/03/16) Sri Lanka University of Colombo Ethics Review Committee (ref: EC-16-063, date 23/05/16) University of Kelaniya Ethics Review Committee (ref: P/62/05/2016, date 11/05/16) UK West Midlands - Solihull Research Ethics Committee (ref: 16/WM/0171, date 14/04/2016) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available to others on completion of the research, by application to the Steering Committee.CIConfidence intervalCONSORTConsolidated Standards of Reporting TrialsCRTControlled randomized trialICCIntraclass Correlation CoefficientITTIntention to treatLSMLifestyle modificationMETMetabolic equivalentsOROdds ratioSAPStatistical Analysis PlanSDStandard deviationT2DType 2 diabetes